PRESS RELEASE
Global Bioenergies: strong reduction of
the loss in 2023 thanks to a significant increase in commercial
activity
-
Sales exceeding €3M for the first time
-
Consolidated net loss significantly improved to -€8.7M
compared to -€12M in 2022
-
Gross cash position of €11.7M at 31 December 2023 compared
to €8.8M the previous year
-
Successful commercialization of the first tons of
Isonaturane™ 12 to several customers including
L'Oréal
-
ASTM certification received for the production of
sustainable aviation fuels
-
Continued collaboration with Shell for the development of
low-carbon road fuels
-
Major government funding granted, totalling €21M notably
for the construction of the cosmetics plant
-
Key personnel recruitment, in particular an Industrial
Director and a Chief Business Officer
-
Progress in CSR approach: EcoVadis bronze medal and 30%
reduction in electricity consumption at the Evry premises in two
years
Evry, 6 March 2024 – 5:45pm
CET: The Board of Directors of Global Bioenergies held
yesterday approved the 2023 annual accounts, which show that the
loss has been significantly reduced at €8.7 million1.
Samuel Dubruque, Chief Financial Officer
of Global Bioenergies, comments: "2023 is marked by strong
sales growth, reaching a record level of over €3 million, and by a
significant improvement in net income. This performance reflects
the major progresses made by the Group in 2023. On the cosmetics
side, we were able to meet our customers' expectations by
delivering our first commercial batches. On the aviation side, ASTM
certification has propelled our innovation into the very select
circle of technologies that can be used in all airplanes worldwide.
To support these efforts, the Group obtained €21 million in
financial support from the government, including €4.8 million
received to date; financial visibility is ensured for 2024."
Marc Delcourt, co-founder and Chief
Executive Officer of Global Bioenergies, adds:
" Building on these achievements and the resources at its
disposal, the Group is now fully focused on realizing its
ambitions: financing and building its future plant to address the
cosmetics sector on the one hand, and executing its roadmap to
maximize the value of our innovation in sustainable aviation fuels
(SAF) on the other. We bring unique breakthrough technologies to
each area, always with the same objective: to move away from fossil
resources, maintain performance and build a sustainable world
together."
-
Group Profit & Loss Account
€ thousands |
from 01/01/23to
30/12/202312 months |
from 01/01/22to
31/12/202212 months |
from 01/01/21to
31/12/202112 months |
|
|
|
|
Operating
income |
8,910 |
1,715 |
3,881 |
Sales |
3,249 |
698 |
101 |
Operating subsidies |
2,698 |
895 |
3,024 |
Change in inventory of finished products |
1,530 |
-118 |
731 |
Other |
1,432 |
240 |
25 |
Operating expenses |
18,621 |
14,907 |
17,229 |
Operating profit (loss) |
-9,711 |
-13,192 |
-13,348 |
|
|
|
|
EBITDA |
-6,878 |
-11,383 |
-11,093 |
|
|
|
|
Financial
profit |
107 |
-95 |
-131 |
Profit before
tax |
-9,604 |
-13,287 |
-13,479 |
Non-recurring
items |
-239 |
-147 |
-2 |
Income tax |
-1,187 |
-1,447 |
-1,708 |
|
|
|
|
Net income (loss) |
-8,656 |
-11,986 |
-11,773 |
Revenue was €3.2 million for the 2023 financial
year, a sharp increase compared to previous years, following the
delivery of the first orders of several tons of Isonaturane™ 12.
Grant income is also up thanks to the successes of two major
European research programs, Rewofuel and Optisochem. At the same
time, Global Bioenergies received financial support from ADEME for
the Prénidem project, which enabled the Company to record €0.8
million in grant income over the 2023 financial year.
Details of operating expenses (€
thousands) |
2023 |
2022 |
2021 |
Personnel |
4,553 |
4,287 |
4,091 |
Industrialization/Commercialization |
8,778 |
6,713 |
8,117 |
Laboratory |
346 |
343 |
680 |
Rentals and maintenance |
1,034 |
850 |
834 |
Intellectual property |
390 |
323 |
562 |
Amortization |
1,590 |
703 |
1,474 |
Other |
1,931 |
1,688 |
1,471 |
TOTAL |
18,621 |
14,907 |
17,229 |
Operating expenses are increasing with the
production of several tons of Isonaturane™ 12, and
amortization charges are up sharply following the commissioning of
the Pomacle industrial production facility during 2022.
• Group Balance
Sheet
Assets (€ thousands) |
31/12/23 |
31/12/22 |
31/12/21 |
|
Liabilities (€ thousands) |
31/12/23 |
31/12/22 |
31/12/21 |
|
|
|
|
|
|
|
|
|
Intangible
assets |
327 |
539 |
800 |
|
Capital |
906 |
749 |
743 |
Tangible
assets |
2,471 |
3,612 |
637 |
|
Share
premium |
10,538 |
16,029 |
29,289 |
Assets under
construction |
77 |
401 |
1,897 |
|
Balance carried
forward |
-2,769 |
-2,708 |
-4,697 |
Financial
assets |
341 |
1,546 |
1,544 |
|
Profit
(loss) |
-8,656 |
-11,986 |
-11,773 |
|
|
|
|
|
Equipment
subsidies |
2,758 |
463 |
- |
|
|
|
|
|
|
|
|
|
NON-CURRENT ASSETS |
3,217 |
6,097 |
4,879 |
|
EQUITY |
2,778 |
2,547 |
13,562 |
|
|
|
|
|
|
|
|
|
IBN and
derivatives inventories |
219 |
2,342 |
1,793 |
|
PROVISIONS |
53 |
110 |
61 |
Consumables
inventories |
350 |
250 |
250 |
|
|
|
|
|
Receivables |
2,247 |
3,647 |
3,524 |
|
Conditional
advances and loans |
12,451 |
11,486 |
12,454 |
Cash |
11,673 |
8,768 |
20,931 |
|
Trade
payables |
2,411 |
5,580 |
3,520 |
Marketable
securities |
171 |
173 |
147 |
|
Tax and social
security liabilities |
559 |
502 |
1,185 |
Prepaid
expenses |
378 |
300 |
261 |
|
Other debts and
deferred income |
3 |
1,352 |
1,003 |
|
|
|
|
|
|
|
|
|
CURRENT ASSETS |
15,038 |
15,480 |
26,907 |
|
PAYABLES and DEFERRED INCOME |
15,423 |
18,921 |
18,163 |
|
|
|
|
|
|
|
|
|
TOTAL ASSETS |
18,254 |
21,577 |
31,785 |
|
TOTAL LIABILITIES |
18,254 |
21,577 |
31,785 |
The balance sheet shows an increasing cash
position reaching €11.7 million as of 31 December 2023, ensuring
the financial visibility of the Company for the entire 2024
financial year. Furthermore, the collection of the first tranche of
the financing granted by the French government as part of the
France 2030 plan for the construction of the world's first
full-size biosourced isobutene plant (€4.1 million) leads to an
increase in the equipment subsidies item.
-
2023 highlights and recent events
Successful commercialization of the
first tons of Isonaturane™ 12 to several customers including
L'Oréal
In the first half of 2023, Global Bioenergies
successfully supplied several tons of Isonaturane™ to major players
in the cosmetics industry, including L'Oréal. As a reminder,
Isonaturane™ is the first equivalent of natural origin to fossil
isododecane, one of the most widely used ingredients in cosmetics.
In both cases the structure of the molecule is the same, only its
origin differs. Thanks to this unique innovation, cosmetic
products, from make-up to skincare, gain in naturalness while
guaranteeing customers the same level of performance.
These first sales initiate the scale-up of
Global Bioenergies, which is now focusing on building a full-size
plant to significantly increase the quantities produced and be able
to address ever larger markets. In this context, the Company has
decided not to continue the activities of its brand LAST™. This
brand, a showcase for the Company launched in 2021, made it
possible to demonstrate the quality of its ingredients and to
understand the complex cosmetics market. Its mission is now
accomplished and the Company is now directing all its efforts
towards its larger-scale projects.
ASTM certification received for the
production of sustainable aviation fuels
As a reminder, the airline industry requires the
fuel used in airplanes to be ASTM certified. Sustainable aviation
fuels also undergo this complex, multi-year process, according to
the ASTM D7566 standard. This standard allows them to be considered
as 'drop-in' fuels, meaning they can be blended with fossil
kerosene and used safely in existing airplanes and infrastructures
worldwide.
In June 2023, Global Bioenergies obtained this
ASTM certification for its sustainable aviation fuels production
technology. This is the starting point for the Company to position
itself in the emerging SAF market, where many questions remain
unanswered: Which technologies will be the most mature? Which
technologies will be the most commercially competitive? What will
be the production capacities able to meet the immense production
volumes demanded by the RefuelEU regulations? Current production
does not exceed 500,000 tons, whereas more than 12 million tons are
expected to be needed worldwide by 2030, and will have to be
multiplied by a ten-fold factor by 2050.
Major public funding granted, notably
for the construction of the first full-scale biobased isobutene
plant
The year 2023 was also marked by the very strong
support of the French government in the pursuit of the Company's
activities. With the signing of the so-called "Prénidem" project in
March 2023, ADEME is once again supporting the Group's
technological optimization activities to the tune of €4.4 million.
The French government then granted Global Bioenergies a €16.4
million package (in the form of subsidies and repayable advances)
to build the world's first full-scale biobased isobutene plant,
designed to produce ingredients for the cosmetics industry. The
first tranche of financing, amounting to €4.1 million, was received
at the end of 2023.
Continued collaboration with Shell in
the development of low carbon road fuels
At the beginning of 2023, the Company signed an
extension to the collaboration agreement established the previous
year with Shell for low-carbon road fuel production pathways.
Following the conclusions of this research, a new phase of
collaboration was initiated in January 2024 to support a specific
technology pathway.
Continuing to structure
teams
In order to support and accelerate the evolution
of its activities towards industry and commercialization, the
Company has recruited several new positions. On the industrial
side, an experienced Industrial Director and an LCA Project Manager
have been recruited to carry out our future plant project in
accordance with our environmental convictions. On the commercial
side, the recruitment of a Chief Business Officer and a Quality
Manager allow the Company to meet the expectations of our
customers.
Progress of our CSR approach: EcoVadis
bronze medal and concrete actions
For its first evaluation, Global Bioenergies has
reached the top 30% of the best performing companies in terms of
CSR among the 110,000 companies evaluated worldwide by the rating
agency. This award recognizes the CSR approach adopted by the
entire company over the last few years, which has led to a 30%
reduction in electricity consumption at the Evry laboratory between
2021 and 2023. In 2023 alone, the savings of 100 MWh are equivalent
to the private consumption of all Global Bioenergies employees.
Increase in the resources allocated to
the liquidity contract with the brokerage firm Gilbert
Dupont
Under the liquidity contract entrusted by Global
Bioenergies to the brokerage firm Gilbert Dupont, an additional
contribution of €50,000 was made on 6 March 2024.
As a reminder, on the full-year report of 29
December 2023, the following assets appeared on the liquidity
account:
- Number of shares:
11,427
- Cash balance of
the liquidity account: €16,691.74
About GLOBAL BIOENERGIES
Global Bioenergies substitutes products of
fossil origin with products of natural origin. In their quest for
naturalness without compromising on performance, the cosmetics
players are the Company's first customers. By 2027, the Company
will be operating its innovative process in a large-scale plant. By
2030, the Company plans to become a leader in the huge emerging
market for sustainable aviation fuels, in order to fight against
global warming. Global Bioenergies is listed on Euronext Growth in
Paris (FR0011052257 - ALGBE). L'Oréal is its largest shareholder,
with a 13.5% stake.
Contacts
GLOBAL BIOENERGIES+33 (0)1 64 98 20
50invest@global-bioenergies.com Follow our
news Receive information about Global Bioenergies
directly by subscribing to our news feed on
https://www.global-bioenergies.com/inscription-newsletter/ Follow
us on LinkedInGlobal Bioenergies |
|
NewCap – Investor
relationsLouis-Victor DelouvrierAurélie
Manavarereglobalbioenergies@newcap.eu+33 (0)1 44 71 94
94 NewCap – Media relations Nicolas
Merigeauglobalbioenergies@newcap.eu+33 (0)1 44 71 94 98 |
1 The accounts were audited by the Statutory Auditor. The annual
financial report will be published by April and the accounts will
be certified at the same time.
- Global Bioenergies_2023_Annuals results_060324_EN
Global Bioenergies (EU:ALGBE)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Global Bioenergies (EU:ALGBE)
Historical Stock Chart
Von Dez 2023 bis Dez 2024